Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

Kathryn C. Arbour, Laura Mezquita, Niamh M. Long et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Management of Cancer in the Older Person: A Practical Approach

Lodovico Balducci, Martine Extermann · The Oncologist · 2000 · 944 citations

Medicine, Geriatric Medicine, Oncology +17

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster et al. · Clinical Cancer Research · 2018 · 361 citations · Full text

Medicine, Immunology, Oncology +17

CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly

Laura Haynes, Sheri M. Eaton, Eve M. Burns et al. · Proceedings of the National Academy of Sciences · 2003 · 270 citations · Full text

Life Sciences, Cell Biology, Immunology +17